Silver Book Fact

It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall the study finds that the value of increased longevity through these potential innovations will greatly exceed the rising costs of health care.

Vernon J, Goldberg R, Dash Y, Muralimohan G. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477

Reference

Title
Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?
Publisher
Working Paper — Pending Publication
Publication Date
2007
Authors
Vernon J, Goldberg R, Dash Y, Muralimohan G
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, every $1 spent on Alzheimer’s research would save Medicare $10 by 2015 and $25 by 2025.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the total costs of care for people with the disease by…  
  • Impact of a 5-Year Delay in Onset on Costs, Americans Age 65 and Older with Alzhemier’s Disease, 2010-2050  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 out-of-pocket costs for individuals and families dealing with the…  
  • Based on rates of admission in 1998, delaying admission of Alzheimer’s patients to nursing homes by 1 month could save as much as $1.12 billion a year.